Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) agreed to engage China Resources Kelun as a downstream distributor and seller for some of its commercialized products from time to time during Oct. 31, 2024, and Dec. 31, 2025, a Thursday Hong Kong bourse filing said.
Under the agreement, the company will sell its commercialized products to the other party from time to time, which the other party will distribute downstream or sell directly to the consumers.
The annual caps set for the transactions are 10 million yuan for 2024 and 15 million yuan for 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。